HLA Today

Get started with HLA Today

Save time and improve AML outcomes with HLA Today

The National Marrow Donor Program® (NMDP)/Be The Match® is now offering HLA Today – a free program for patients newly diagnosed with acute myeloid leukemia (AML) aimed at improving patient outcomes.

HLA Today is a focused effort to conduct HLA typing at the time of diagnosis and provide you with your patient’s preliminary donor search report. Our goal is to make treatment decision-making easier by providing you with critical information as early as possible in a patient’s disease course.

 

Why HLA Today?

Allogeneic hematopoietic cell transplantation (HCT) in early stage disease has been shown to significantly improve survival for patients with AML who have intermediate- or poor-risk cytogenetics. [1,2]

Randomized controlled clinical data demonstrated the clinical benefit of early HLA typing. In a study of more than 700 patients with AML (SWOG 1203), HLA typing was expedited for all patients with poor-risk cytogenetics at the time of diagnosis. The following results were seen:

  • 64% transplant rate in first complete remission (CR1) compared to the historical rate of 40% (p<0.001)
  • 45% increase in two-year relapse-free survival (32% vs 22% historical rate, p=0.05)

Researchers concluded that better outcomes in poor prognosis patients with AML may be achieved by initiating the process to find donors at the time of diagnosis and performing HCT consistently early in CR1. [3]

 

Better information means better treatment decisions

National Comprehensive Cancer Network® (NCCN) guidelines indicate HLA typing should be completed for all patients with AML who may be eligible for allogeneic HCT. [4] By completing HLA typing on all recently diagnosed patients with AML, those patients who have intermediate- and poor-risk disease features can proceed to HCT consultation without delay. Identifying potential donors and preparing for HCT early increases the likelihood that the patient can undergo transplant at the optimal time.

 

How HLA Today works

We will supply you with buccal swab kits for patients diagnosed with AML. After collecting a swab sample from your patient, you send the kit to the NMDP/Be The Match for high-resolution HLA typing.

The NMDP/Be the Match provides you with HLA typing results and a preliminary search report on unrelated donor matches for your patient from the Be The Match Registry®. You can expect to receive the HLA typing and the preliminary search report seven to 10 business days after submitting the kit. There is no cost to you or your patient.

A physician from the NMDP/Be The Match will connect with you by phone to discuss the report and answer any questions.

Fill out the form to contact us to get started with HLA Today.

  1. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014; 124(16): 2596-2606.
  2. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583.
  3. Pagel JM, Othus M, Garcia-Manero G, et al. Feasibility of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission: Results of the transplant objective from the SWOG (S1203) randomized phase III study of induction therapy using standard 7+3 therapy or idarubicin with high-dose cytarabine (IA) versus IA plus vorinostat. Blood. 2016; 128(22): 1166.
  4. NCCN Clinical Practice Guidelines in Oncology Version 1.2019 Acute Myeloid Leukemia